Cannabinoid API Combinations for Synergistic Cancer Cell Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments lack effective and alternative therapies that can target various types of cancer cells, and existing cannabinoid-based treatments may have limitations in efficacy and synergistic combinations.
Innovation Solution
Development of an active pharmaceutical ingredient (API) comprising cannabidiol (CBD) in combination with other cannabinoids such as cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), or tetrahydrocannabivarin (THCV) for use in treating breast, lung, pancreatic, melanoma, ovarian, gastric, renal, and bladder cancers, with specific ratios and formulations for optimal synergistic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single cannabinoid treatments (e.g., CBD alone) are used, then treatment simplicity is maintained, but therapeutic efficacy is limited
Solution Approach 1:
The patent combines multiple cannabinoids (CBD with CBG, CBGA, CBDA, or THCV) into a single pharmaceutical composition to achieve synergistic anti-cancer effects. The combination of cannabinoids works together to enhance therapeutic efficacy beyond what single cannabinoids can achieve alone, while still being administered as a unified treatment regimen.
Solution Approach 2:
The invention creates a composite pharmaceutical composition containing multiple cannabinoid compounds in specific ratios. This composite approach leverages the complementary mechanisms of action of different cannabinoids to produce a more effective anti-cancer therapy, where the whole is greater than the sum of its parts.
2Reliability
If combination therapies are used, then therapeutic efficacy is improved, but treatment complexity increases
Solution Approach 1:
Multiple cannabinoids are merged into a single pharmaceutical composition that can be administered together, simplifying the treatment protocol while maintaining the synergistic benefits of combination therapy. The composition delivers multiple active compounds simultaneously, avoiding the need for separate administrations of each cannabinoid.
3Reliability
If high doses of single cannabinoids are used, then anti-cancer effect is enhanced, but side effects increase
Solution Approach 1:
The invention changes the concentration parameters by using lower doses of multiple cannabinoids in combination rather than high doses of single cannabinoids. The synergistic interaction allows each component to be present at lower concentrations while achieving greater overall efficacy, thereby reducing toxicity and side effects.
Solution Approach 2:
The multiple cannabinoids act as intermediaries that work together to enhance anti-cancer effects through complementary mechanisms. This cooperative action allows for reduced individual dosing while maintaining or improving therapeutic outcomes, thereby reducing harmful side effects associated with high-dose monotherapy.
Data Source
AI summary
The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).